Reactivos e instrumentos para inmunología, biología celular y biología molecular.

Q-VD-OPH [1135695-98-5]

Imprimir

Referencia NB-64-00441-5mg

embalaje : 5mg

Marca : Neo Biotech

Solicitar más información

Remove All

Q-VD-OPH

(Synonyms: Quinoline-Val-Asp-Difluorophenoxymethylketone) Copy Product Info

Synonyms: Quinoline-Val-Asp-Difluorophenoxymethylketone

Catalog No. T0282 Copy Product Info

Purity: 99.96%

Q-VD-OPh is an irreversible caspase inhibitor with an IC50 value of 48 nM against caspase-7 and between 25 and 400 nM against caspase-1, 3, 8, 9, 10, 12. Q-VD-OPh inhibits HIV infection and can cross the blood-brain barrier.

Cas No. 1135695-98-5

With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.

For research use only—not for human use. No sales to individuals. Use as intended only.

Select Batch

Purity:99.96%

Product Introduction

Bioactivity

Description	Q-VD-OPh is an irreversible caspase inhibitor with an IC50 value of 48 nM against caspase-7 and between 25 and 400 nM against caspase-1, 3, 8, 9, 10, 12. Q-VD-OPh inhibits HIV infection and can cross the blood-brain barrier.
Targets & IC50	Caspase-9:25 nM-400 nM, Caspase-12:25-400 nM, Caspase-3:25 nM-400 nM, Caspase-10:25-400 nM, Caspase-1:25 nM-400 nM, Caspase-8:25 nM-400 nM, Caspase-7:48 nM
In vitro	METHODS: The apoptosis of cardiomyocytes treated with Q-VD-OPH was detected by Flow Cytometry RESULTS: Q-VD-OPH could protect cardiomyocytes from virus-induced apoptosis. [1]
In vivo	METHODS: To study the effects of Q-VD-OPH on apoptosis, immune response, and virus replication, SIVmac251 virus was administered intravenously to Chinese macaques to mimic HIV infection, and Q-VD-OPH (20 mg/kg) was administered intravenously to Chinese macaques on days 5, 7, 9, 11, and 14. RESULTS: Q-VD-OPH significantly reduced the level of apoptosis of T cells in peripheral lymph nodes. The number of TUNEL+ cells was significantly lower in the Q-VD-OPh treated group than in the untreated group. Q-VD-OPH treatment significantly increased CD4+ T cell count and CD4/CD8 ratio and decreased viral replication. [2] METHODS: To study the protective effect of Q-VD-OPH on ischemic acute renal failure (ARF), Q-VD-OPH (120 mg/kg) was intraperitoneally injected into mice. RESULTS: Q-VD-OPH inhibited the expression of caspase-1 and IL-18 and neutrophil infiltration in ischemic ARF mice. [3] METHODS: To study the protective effect of Q-VD-OPH on myocardial injury, Q-VD-OPH (50 mg/kg) was intraperitoneally injected into virus-infected mice on days 3 to 6. RESULTS: Q-VD-OPH protected against virus-induced myocardial injury by inhibiting caspase activity. [1] METHODS: To study the therapeutic effect of Q-VD-OPH on AD, TgCRND8 mice were intraperitoneally injected with Q-VD-OPH (10 mg/kg) three times a week for three months. RESULTS: Q-VD-OPH inhibited caspase-7 activation and the pathological changes associated with tau protein, including caspase cleavage. [4]
Synonyms	Quinoline-Val-Asp-Difluorophenoxymethylketone
Kinase Assay	Enzyme assay is conducted in buffer containing 25 mM Tris, pH 8.0, 1 mM DTT, 1 mM spermine, 50 mM KCl, 0.01% Nonidet P-40, and 1 mM MgCl2. PARP reaction contains 0.1 μCi [3H]NAD+ (200?000 DPM), 1.5 μM NAD+, 150 nM biotinylated NAD+, 1 μg/mL activated calf thymus, and 1?5 nM PARP-1. Autoreactions utilizing SPA bead-based detection are carried out in 50 μL volumes in white 96-well plates. Compounds (e.g., MK-4827) are prepared in 11-point serial dilution in 96-well plate, 5 μL/well in 5% DMSO/Water (10× concentrated). Reactions are initiated by adding first 35 μL of PARP-1 enzyme in buffer and incubating for 5 min at room temperature and then 10 μL of NAD+ and DNA substrate mixture. After 3 h at room temperature, these reactions are terminated by the addition of 50 μL of streptavidin-SPA beads (2.5 mg/mL in 200 mM EDTA, pH 8). After 5 min, they are counted using a TopCount microplate scintillation counter. IC50 data is determined from inhibition curves at various substrate concentrations[1].
Cell Research	Caspase inhibitors are added at the indicated concentrations 30 minutes prior to the addition of apoptotic stimuli. Viability and cell number are determined by trypan blue exclusion from three random fields of greater than 200 cells/field. All experiments are performed a minimum of three times.(Only for Reference)

Chemical Properties

Molecular Weight	513.5
Formula	C₂₆H₂₅F₂N₃O₆
Cas No.	1135695-98-5
Smiles	CC(C)[C@H](NC(=O)c1ccc2ccccc2n1)C(=O)N[C@@H](CC(O)=O)C(=O)COc1c(F)cccc1F
Relative Density.	1.346 g/cm3 at 20℃

Storage & Solubility Information

Storage

Keep away from moisture,Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

Ethanol: 100 mg/mL (194.74 mM), Sonication is recommended.

DMSO: 260 mg/mL (506.33 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (9.74 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

Ethanol/DMSO

	1mg	5mg	10mg	50mg
1 mM	1.9474 mL	9.7371 mL	19.4742 mL	97.3710 mL
5 mM	0.3895 mL	1.9474 mL	3.8948 mL	19.4742 mL
10 mM	0.1947 mL	0.9737 mL	1.9474 mL	9.7371 mL
20 mM	0.0974 mL	0.4869 mL	0.9737 mL	4.8685 mL
50 mM	0.0389 mL	0.1947 mL	0.3895 mL	1.9474 mL
100 mM	0.0195 mL	0.0974 mL	0.1947 mL	0.9737 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 µL Tween 80 and mix well until fully clarified.

3) Add 450 µL Saline,PBS or ddH₂O and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

Keywords

QVD-OPHQ-VD-OPHQVDOPHQ VD OPHInhibitorinhibitHuman immunodeficiency virusHIVProteaseHIV ProteaseHIVCaspase-9Caspase-8Caspase-3Caspase-1Caspase

Related Tags: Q-VD-OPH chemical structure | Q-VD-OPH in vivo | Q-VD-OPH in vitro | Q-VD-OPH formula | Q-VD-OPH molecular weight